My colleague, Andre, spoke about this topic here last week, and now we have compiled insights on this matter from conversations with industry and from our own research.
The report addresses issues like:
- The impact of comparability on orphan drug development
- What happens in Europe?
- Dealing with regulatory frameworks
- Consequences to market access and patients globally
For more information on this hot topic, check out World Orphan Drug Congress USA.